Loading…
← CockpitCompetitor Analysis › MOREPENLAB.NS Morepen Laboratories LimitedOpen in the cockpit ↗

Morepen Laboratories LimitedMOREPENLAB.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum leader 94
Mkt cap
$542M
US dollars, full cap
Free float
57%
of shares outstanding
$/day
$5.57M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-3.6 pp
WACC 16.2%
Hurdle
n/a
no reverse DCF
Close · INR₹92.37
1D+2.2%
1W-4.5%
1M-24.0%
3M+4.4%
6M+120.7%
YTD+124.9%
1Y+96.2%
ATR %7.6%
Beta1.00
52w lowhigh38.7% off high

What Morepen Laboratories does

Employees: 3,069

Morepen Laboratories at a glance

Size Morepen Laboratories (MOREPENLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $542M, the 823rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹92.37 on 18 Nov 2026.

Performance Over six months the shares gained 120.7%, against -20.2% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 19 in its peer set.

Growth Revenue grew 30.2% over the last twelve months (peer median -2.7%); the operating margin is 10.6% (peer median 6.4%).

Valuation It trades at 2.2× enterprise value to sales against a peer median of 5.6× (7th cheapest of 19).

Capital Return on invested capital runs 3.6 points below its cost of capital (16.2% WACC).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026MOREPENLAB.NS 217Peer median 81
Six months, rebased to 100: Morepen Laboratories against the median of its 20 peers (local-currency closes).

Morepen Laboratories financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹22.9B₹18.0B₹18.1B₹16.8B₹14.1B
Revenue growth—0%+7%+19%—
Gross profit₹6.34B₹3.18B₹3.17B₹3.26B₹2.19B
EBITDA₹2.76B₹1.22B₹1.70B₹1.50B₹764M
Net income₹1.89B₹949M₹1.18B₹962M₹387M
Free cash flown/a-₹693M-₹1.00B-₹117M-₹1.39B
Capital expendituren/a₹2.04B₹2.38B₹813M₹460M
Total debt₹3.23B₹2.08B₹1.05B₹290M₹252M

Quarterly statements and history in the cockpit →

Morepen Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-20%0%+20%SENORES0026886032224559ZVRAACRSSUPRIYA002393688356ENTXALMSEGTXMOREPENLAB.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Morepen Laboratories is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×25×50×75×SENORES0026886032224559ZVRAACRS000919SUPRIYAEVONILE688356ALMS603676EGTXMOREPENLAB.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Morepen Laboratories is the large dot.

Morepen Laboratories competitors and peer comparison

How Morepen Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Morepen Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureMOREPENLAB.NSPeer medianRank in peer set
1-month return-24.0%-7.2%4th lowest of 20
6-month return+120.7%-20.2%2nd highest of 19
Distance from 52-week high-38.7%-40.7%9th highest of 20
Revenue growth (TTM)+30.2%-2.7%4th highest of 20
Operating margin10.6%6.4%9th highest of 19
EV / Sales2.2×5.6×7th cheapest of 19
ROIC minus cost of capital-3.6 pp-1.0 pp7th lowest of 17
EV / EBITDA18.5×7.7×3rd most expensive of 7
Net debt / EBITDA0.2×0.3×4th least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%2.2×n/an/a
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%7.4×n/an/a
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%1.8×1.0%+9.7%
Chimin Health Management 603222.SSChina$533M-31%+1%-28%6.6×n/an/a
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%1.0×-12.3%+11.1%
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%2.4×-4.9%+51.6%
Boryung 003850.KSSouth Korea$554M-13%+6%6%0.9×-3.1%+12.6%
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%69.1×n/an/a
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%0.7×2.4%+5.0%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%5.5×28.2%+15.8%
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%16.2×49.3%-1.5%
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%1.2×-5.8%+4.1%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%6.2×n/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%8.7×36.4%+11.2%
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%5.6×n/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%23.9×n/an/a
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%1.9×-15.4%+2.8%
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a

Questions

Which companies are Morepen Laboratories's closest peers?
The cockpit's peer set: Senores Pharmaceuticals (SENORES.NS), Jinhe Biotechnology (002688.SZ), Chimin Health Management (603222.SS), Zeria Pharmaceutical (4559.T), Zevra Therapeutics (ZVRA), Boryung (003850.KS), Electra Therapeutics (ETRA), Aclaris Therapeutics (ACRS).
Is Morepen Laboratories expensive compared with its peers?
On ev / sales it trades at 2.2× against a peer median of 5.6×, 7th cheapest of 19 in its peer set.
How has Morepen Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +120.7% against -20.2% for the median peer; over one year +96.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.